Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (TSXV:
$KHRN.V) (TSX: $AVCN.CA) (TSXV: $NRTH.V) (OTC: $KALY)
Delta, Kelowna, BC –August 23, 2019 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/08231KHRN-AVCN-NRTH-KALY.asp
Good afternoon and welcome to another episode of
Investorideas.com "Potcast" featuring cannabis news, stocks to watch
as well as insights from thought leaders and experts.
In
today’s podcast we look at a few early announcements.
But
first, Geocann announced that the company has successfully
commercialized the first CBG soft gel products that utilize the multi-patented
VESIsorb® delivery system for optimal absorption and measured
bioavailability. The initial step is utilizing proprietary extraction
technology to isolate and concentrate the CBG that allows Geocann to use its
technical formulation expertise to address the active ingredient’s performance
as it relates to dissolution, absorption, and bioavailability.
The
first of two formulations is a combination of CBG and cannabidiol (CBD) while
the second is a mono-CBG formulation. Both products include strategic
inclusions of beta-caryophyllene (BCP) which has been shown to have synergistic
effects as agonists for the CB2, 5-HT1A and glycine receptors.
“These
product launches further advance Geocann’s leadership position as product
development specialists that provide science-backed solutions to the industry’s
formulation challenges,” said Marc Weder, Chief Scientific Officer. “The
marketplace is demanding advancements beyond just CBD products and we are supremely
positioned to deliver these solutions with more than three decades of research
and product development expertise.”
Weder
states that while the interest is high to include CBG (and other emerging
cannabinoids and terpenes) in new formulations, the poor solubility and
dissolution must be addressed to provide superior product solutions with the
optimized absorption, bioavailability, and maximum therapeutic benefits
consumers are seeking.
“Geocann
has accomplished these results and has successfully transferred a rigorous
product development protocol to the large-scale commercial production of soft
gel capsules, topicals, foods, beverages, and sublinguals that combine these
active ingredients with the VESIsorb® technology,” said Weder.
Geocann
has worldwide exclusivity for cannabinoids formulated with VESIsorb®,
and the company is quickly partnering with strategic brand leaders in key
channels of distribution to deliver its robust portfolio of patent-protected
products.
“The
combination of CBD, CBG, and BCP powered by VESIsorb® in an elegant
soft gel capsule is an important industry milestone,” said Jesse Lopez, CEO and
founder. “Geocann will continue to pioneer the advancement of new cannabinoids,
like CBG, CBN, and THCV, as it’s a privilege to offer these first-to-market
opportunities to our brand partners.”
Khiron Life Sciences Corp. (TSXV: KHRN)
(OTCQB: KHRNF) provided an update on its cultivation and production
operations near Ibague, Colombia, where it has achieved significantly expanded
analysis, extraction and purification capabilities across its cultivation
facility.
Khiron
currently owns and operates one of the most sophisticated medical cannabis
cultivation and processing facilities in Latin America. Building on the
completion of the facility announced on June 2, 2019, the state-of-the-art,
14,000 square foot GMP and ISO 17025 compliant lab now includes full
capabilities in the following:
●
Ultra
high and High performance liquid chromatography ("UHPLC & HPLC")
technology, gas chromatography technology, microbiology testing, and heavy
metals for testing flower and extract samples –Through the use of these
in-house techniques, Khiron can quickly and accurately analyze samples,
identify active cannabis components, and ensure that the products are extracted
and purified to meet local regulations on THC and CBD concentrations.
●
Stability
testing – Stability tests provide evidence on how cannabis products vary over a
given time period and under the influence of environmental factors. Khiron
currently has robust stability testing capacities in place, with studies
designed to evaluate and ensure the quality, safety and efficacy of its products,
across various stages of extraction, as well as final product. In Colombia, stability data is needed to
receive quotas for the production and domestic commercialization of THC
extracts. As part of the Company's commitment to high quality standards,
stability testing for extracts and final products are necessary before shipping
product to consumers.
●
Vertical
integration – Leveraging the Company's cultivation, extraction and purification
capabilities, Khiron has the ability to manage all stages of cannabis
production, from soil to flower to extract, entirely within its own
facility. Its vertically integrated
capabilities serve to maximize efficiency and reliability across the cannabis
supply chain, allowing the Company to streamline operations as it moves towards
the sale and distribution of its products.
Alvaro
Torres, Khiron CEO and Director, stated, "With advanced analysis,
extraction and purification capabilities in place, the company has
performed the analytical and stability
tests required by the authorities to launch medical products and we remain on
track for full commercialization of the grow site, anticipated in Q3 2019. Our
significant investment in the Company's Ibague facility, primarily to target a
market of 6 million patients in Colombia, ensures Khiron remains focused on its
core strategy to serve the domestic market in Latin America."
Through
scalable and flexible operations, the Company has designed its cultivation
capabilities to work within the most up-to-date country quota to meet domestic
demand, including to serve more than 119,000 patients at the Company's IILANS
clinics. Based on the total allocation to the country, the Government of
Colombia allocates annual quotas reflecting the operational plan and production
estimates as outlined in the licence submissions, with the ability to request
additional capacity to meet market demands. Country production quotas for 2020
will be announced by the INCB in January 2020.
Avicanna Inc. (TSX: AVCN) a
biopharmaceutical company focused on the development, manufacturing and
commercialization of plant-derived cannabinoid-based products announced that its
subsidiary, Santa Marta Golden Hemp S.A.S., has completed its first export of
purified CBD from Colombia to Canada for research and development purposes.
Aras Azadian, Chief Executive Officer of Avicanna
commented "We are thrilled to complete our first export and proud to be
doing so into Canada. This is another validation of Avicanna's ability to
execute on all of its verticals and demonstrates the success and advantage of
Avicanna's cultivation infrastructure, extraction and purification capacity,
and regulatory expertise."
Health Canada issued three authorizations to SMGH on June
28, 2019 to allow for the import of CBD isolates and cannabis resin into Canada
from Colombia for scientific purposes. The CBD isolates cleared Colombian
border procedures and were exported from Colombia on August 22, 2019.
48North Cannabis Corp. (TSXV:NRTH) announced that
it has entered into a definitive agreement dated August 22, 2019 to acquire
Rare Industries, Inc. ("Quill"),
a U.S. multi-state Vape Technology brand with product distribution in Oregon
and Washington and near-term expansion plans for California and Nevada. The
acquisition marks 48North's first foray into the United States.
Quill, a leader in the manufacturing of
beautifully designed, lifestyle-focused and sleek vape products, specializes in
the development of easy-to-use, controlled-dosage and health-focused disposable
vape pens.
Quill distributes its unfinished branded
proprietary vape delivery hardware to licensed cannabis processors who finish
the products (including by filling the hardware with cannabis extracts) and
distribute the finished products to licensed cannabis retailers. Quill is not
itself engaged in the cultivation, distribution or possession of cannabis in
the United States.
This year, in addition to Quill's
established products, the company is launching a full-spectrum, hemp based,
CBD-specific, internationally distributed, all-in-one vaporizer pen. As a
result, 48North-owned products will now have multi-state distribution and the
ability to be licensed globally, where legally permitted.
"48North recognizes the importance
of entering the burgeoning U.S market. I believe that authentic brands and
next-generation products distributed at scale, particularly in the emerging
U.S. market, will be one of the major keys to success in the cannabis
industry," said Alison Gordon, co-CEO of 48North.
"Without question, the Quill suite
of products aligns closely with 48North's growing portfolio of brands. This
acquisition marks a critical step in the Company's goal to become the trusted
leader in the development, manufacturing and distribution of next-generation
cannabis products and brands," Ms. Gordon continued.
48North intends to leverage Quill's
expanding distribution network to accelerate the distribution of the Company's
brand portfolio into the United States. 48North also intends to pursue
opportunities to sell Quill products throughout its existing distribution
network in Canada.
Kali-Extracts, Inc. (OTC:
KALY) published
a new website dedicated to providing information on
the company’s recently introduced CBD Formulation, RespRx, for the treatment of
Chronic Obstructive Pulmonary Disease (COPD) affecting 65 million people
worldwide.
KALY introduced the new CBD
Formulation earlier this week after making a patent
application and trademark registration for the formulation. The website will be continually updated with
information about the patent and application trademark progress and the ongoing
RespRx medical trials and developments as the company advances toward FDA
approval.
In the fourth quarter of last year, 2018,
KALY acquired NCM Biotech (NCMB). NCMB owns and operates a U.S. Patent for
cannabis extraction process. With the
acquisition of NCMB, KALY is now primarily in the business of developing
biopharmaceutical formulations from cannabis extractions for the treatment of
various diseases. KALY now has over four
years of research and development behind cannabis extract formulations
targeting the treatment of Chronic Obstructive Pulmonary Disease (COPD), Cancer
Pain Management, Type 2 Diabetes and Epilepsy.
KALY has implemented a long-term
sustainable overall business strategy.
KALY is not just relying on its biopharmaceutical development strategy
alone to insure the company’s long-term success. KALY, through partnership and independently,
has also introduced to market a number of CBD infused consumer food products
and a new CBD extraction service for hemp farming operations.
The revenue realized in the first six
months of 2019 comes primarily from KALY’s various CBD infusion offerings. KALY realized $165,000 in revenue in the
first six months of 2019. The revenue
results from the company’s cannabis business shift in the fourth quarter of
last year. In the first six months of
2018, KALY reported only $46,000 in sales.
The introduction of KALY’s new cannabis business has seen the company’s
revenue grow over 250% in the first six months of 2019 compared to the first
six months of 2018. KALY also realized
$70,000 in operating net income in the first six months of 2019. KALY reported only nominal operating net
income in the first six months of 2018.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available
on iTunes, Spotify, Google Play Music,
Stitcher, Spreaker, YouTube via
Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment